This page shows the latest Arbutus Biopharma news and features for those working in and with pharma, biotech and healthcare.
Arbutus shares fell around 25% after the news was announced, despite the company’s protestations that it has other compounds coming through its development pipeline. ... Arbutus’ other candidates in development for HBV include follow-on oral capsid
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...